首页> 外文期刊>Oncologie. >The plasmin/plasminogen system and cancer: Molecular study of factors associated with invasiveness and tumour angiogenesis. PAI1, PAI2, uPA, uPAR: Prognostic value and potential therapeutic targets [Relations du système plasminogène-plasmine et cancer: étude moléculaire de facteurs liés à l'invasivité et à la néoangiogenèse. PAI1, PAI2, uPA, uPAR valeur pronostique et cibles thérapeutiques potentielles]
【24h】

The plasmin/plasminogen system and cancer: Molecular study of factors associated with invasiveness and tumour angiogenesis. PAI1, PAI2, uPA, uPAR: Prognostic value and potential therapeutic targets [Relations du système plasminogène-plasmine et cancer: étude moléculaire de facteurs liés à l'invasivité et à la néoangiogenèse. PAI1, PAI2, uPA, uPAR valeur pronostique et cibles thérapeutiques potentielles]

机译:纤溶酶/纤溶酶原系统与癌症:与侵袭性和肿瘤血管生成相关的因素的分子研究。 PAI1,PAI2,uPA,uPA​​R:预后价值和潜在治疗目标[纤溶酶原-纤溶酶系统与癌症的关系:与侵袭性和新血管生成有关的因素的分子研究。 PAI1,PAI2,uPA,uPA​​R的预后价值和潜在的治疗靶标]

获取原文
获取原文并翻译 | 示例
       

摘要

Proteases play a central role in tissue repair and in the process of tumour growth and invasiveness. However, almost all of the proteolytic enzymes are secreted as inactive pro-proteases. With the exception of cathepsin D, which is capable of auto-activation, all the other proteases are activated by a common mechanism involving plasmin, which is itself derived from conversion of plasminogen, an ubiquitous pro-molecule. uPA initiates the conversion of plasminogen to the activated form, plasmin. The specific uPAR receptor is located on the external surface of the cell membrane. It does not have a trans-membrane component and is not linked to pathways of intracellular signal transduction. uPAR, however, can form heterodimers with other membrane molecules, such as growth factor receptors, cellular adhesion molecules etc. When these trans-membrane molecules form heterodimers with uPAR, they activate the pathways of signal transduction, with which they are associated. uPAR is essential for the activation of uPA, but also for cellular motility associated with integrin avβ3. The uPAR - avβ3 complex is formed on the leading edge of the lamellipodia of migrating cells (EMT positive cancerous epithelial cells and activated endothelial cells). PAI1 actively inhibits uPA activity and has a complex role in tumorigenesis: 1. in cell migration during invasion or angiogenesis, it detaches the uPAR - avβ3 complex which is bound to vitronectin and other ligands through uPA. This detachment at the posterior pole of motile cells results from the greater affinity of PAI1 at the uPA binding site on vitronectin. This allows uPAR to be internalised and its re-appearance at the leading edge of the cell. 2. a second and very significant effect is its leading role in transient stabilisation of new capillaries through cooperation between endothelial cells and pericytes, which ensures that the new vessels are functional. This scientific evidence has been assessed by a European expert group with laboratory and clinical input and, in compliance with Hayes' criteria, has led to the establishment of uPA and PAI1as prognostic factors at the highest level of evidence (LOE-I) in breast cancer without node involvement. Together with hormone receptors ER PR and the membrane receptor HER2, these are the only parameters of LOE-I category for breast cancer, and they have appeared as such in international recommendations since 2007 and in the national recommendations of 2009.
机译:蛋白酶在组织修复以及肿瘤生长和侵袭过程中起着核心作用。但是,几乎所有的蛋白水解酶都以无活性的蛋白酶形式分泌。除组织蛋白酶D能够自动激活外,所有其他蛋白酶均通过涉及纤溶酶的共同机制激活,纤溶酶本身源自纤溶酶原(一种普遍存在的分子)的转化。 uPA启动纤溶酶原转化为活化形式的纤溶酶。特定的uPAR受体位于细胞膜的外表面。它不具有跨膜成分,并且不与细胞内信号转导途径相连。然而,uPAR可以与其他膜分子形成异二聚体,例如生长因子受体,细胞粘附分子等。当这些跨膜分子与uPAR形成异二聚体时,它们会激活与之相关的信号转导途径。 uPAR对于激活uPA是必不可少的,而且对于与整联蛋白avβ3相关的细胞运动也是必不可少的。 uPAR-avβ3复合物在迁移细胞(EMT阳性癌性上皮细胞和活化的内皮细胞)的片状脂膜的前沿形成。 PAI1主动抑制uPA活性并在肿瘤发生中具有复杂的作用:1.在侵袭或血管生成过程中的细胞迁移中,PAI1分离通过uPA与玻连蛋白和其他配体结合的uPAR-avβ3复合物。运动细胞后极的这种脱离是由于PAI1在玻连蛋白上uPA结合位点的亲和力更高所致。这样可以将uPAR内部化,并重新出现在单元的前沿。 2.第二个非常重要的影响是它通过内皮细胞和周细胞之间的协作在新毛细血管的瞬态稳定中起主导作用,这确保了新血管的功能。该科学证据已由欧洲专家组进行了实验室和临床投入评估,并且符合Hayes的标准,导致建立了uPA和PAI1作为乳腺癌中最高证据水平(LOE-I)的预后因素没有节点参与。这些与荷尔蒙受体ER PR和膜受体HER2一起是乳腺癌LOE-I类别的唯一参数,自2007年以来在国际建议中以及2009年在国家建议中均已出现。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号